Anlon Healthcare Limited has successfully concluded its postal ballot process, with shareholders approving all five proposed resolutions through electronic voting. Following this approval, the company has announced April 24, 2026 as the record date for implementing the approved corporate restructuring measures and disclosed detailed alterations to its Memorandum of Association capital clause under Regulation 30.

Record Date and Corporate Actions

The company has fixed Friday, April 24, 2026 as the record date for implementing two major corporate actions approved through the postal ballot process. This announcement was made on April 09, 2026, pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Newspaper Publication Disclosure

Anlon Healthcare Limited has fulfilled its regulatory obligations by publishing newspaper advertisements about the record date determination. The company submitted formal disclosure to BSE Limited and National Stock Exchange on April 10, 2026, pursuant to Regulation 30 read with Regulation 47 of SEBI (LODR) Regulations, 2015.

MOA Capital Clause Alterations

Anlon Healthcare Limited has disclosed comprehensive details of alterations in the capital clause of its Memorandum of Association under Regulation 30. The company submitted formal disclosures to BSE Limited and National Stock Exchange on April 09, 2026, detailing two specific alterations following the postal ballot approvals.

Sub-Division Related Changes

The first alteration relates to the sub-division of equity shares, transforming the authorized share capital structure while maintaining the same monetary value.

Authorized Capital Increase

The second alteration involves doubling the authorized share capital to accommodate future growth and the bonus share issuance.

Postal Ballot Results Overview

The postal ballot was conducted exclusively through remote e-voting, with the voting period spanning from March 10, 2026, at 09:00 AM IST to April 08, 2026, at 05:00 PM IST. All five resolutions received overwhelming support from shareholders across different categories.

Regulatory Compliance and Implementation

The disclosure was made in compliance with Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Managing Director Punitkumar Rasadia signed the formal communication to both stock exchanges, confirming the completion of all regulatory requirements for the MOA alterations.

With the record date fixed for April 24, 2026, eligible shareholders will be entitled to receive benefits of both the stock split and bonus share issuance following the implementation of the altered capital clause provisions. The newspaper publications ensure wider dissemination of this important information to all stakeholders.

Anlon Healthcare Limited has successfully completed a strategic acquisition that strengthens its market position in the healthcare sector. The company announced the completion of acquiring 56.67% equity shareholding in Bizotic Life Science Private Limited on March 20, 2026, under Regulation 30 of the SEBI Listing Regulations.

Acquisition Timeline and Regulatory Compliance

The acquisition follows a structured timeline that began with the execution of a Share Purchase Agreement on November 28, 2025. The company had previously disclosed this development through regulatory filings, maintaining transparency with stakeholders throughout the process.

The transaction was completed well ahead of the extended deadline of April 02, 2026, demonstrating efficient execution of the strategic initiative.

Corporate Structure Impact

Following the successful completion of this acquisition, Bizotic Life Science Private Limited has become a subsidiary of Anlon Healthcare Limited. This development represents a significant expansion of the company's operational footprint and strategic capabilities in the healthcare sector.

Regulatory Framework and Compliance

The acquisition has been structured in full compliance with applicable regulatory requirements:

• SEBI Compliance: Executed under Regulation 30(7) of the SEBI Listing Obligations & Disclosure Requirements Regulations, 2015
• Companies Act Compliance: Adheres to Section 179(3)(e) & (j) and all other applicable provisions of Companies Act, 2013
• Disclosure Requirements: All mandatory details were provided in the initial disclosure dated November 28, 2025, as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Strategic Significance

This acquisition marks an important step in Anlon Healthcare Limited's growth strategy, expanding its presence through the addition of Bizotic Life Science Private Limited as a subsidiary. The transaction demonstrates the company's commitment to strategic expansion while maintaining strict adherence to regulatory compliance and transparency standards.

The completion of this acquisition positions Anlon Healthcare Limited for enhanced operational capabilities and market reach through its newly acquired subsidiary, Bizotic Life Science Private Limited.